Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects
作者机构：Department of Liver Surgery and TransplantationLiver Cancer Institute and Zhongshan HospitalFudan UniversityShanghai200032China
出 版 物：《Genes & Diseases》 (基因与疾病（英文）)
年 卷 期：2020年第7卷第3期
页 面：359-369页
核心收录：
学科分类：0710[理学-生物学] 0831[工学-生物医学工程（可授工学、理学、医学学位）] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 0703[理学-化学] 10[医学]
基 金：This work was supported by the Leading Investigator Program of Shanghai municipal government(17XD1401100) the National Key Basic Research Program(973 Program,2015CB554005)from the Ministry of Science and Technology of the People’s Republic of China the National Natural Science Foundation of China(81372655,81472224 and 81672326)to HCS.
主 题：Adjuvant therapy Anti-PD-1 antibody Clinical trial Hepatocellular carcinoma Molecular targeted therapy Recurrence-free survival
摘 要：Tumor recurrence rate after surgery or ablation of hepatocellular carcinoma(HCC)is as high as 70%.However,there are no widely accepted adjuvant therapies;therefore,no treatment has been recommended by guidelines from the American Association for the Study of Liver Disease or the European Association for the Study of the Liver.All the registered trials failed to find any treatment to prolong recurrence-free survival,which is the primary outcome in most studies,including sorafenib.Some investigator-initiated studies revealed that antihepatitis B virus agents,interferon-a,transcatheter chemoembolization,chemokine-induced killer cells,and other treatments prolonged patient recurrence-free survival or overall survival after curative therapies.In this review,we summarize the current status of adjuvant treatments for HCC and explain the challenges associated with designing a clinical trial for adjuvant therapy.Promising new treatments being used as adjuvant therapy,especially anti-PD-1 antibodies,are also discussed.
维普期刊数据库